glp-1 agonist fda approval just approved orforglipron (Foundayo), Eli Lilly's oral receptor for obesity. In the ATTAIN-1 phase 3 trial (n=3,127), published in the New England Journal of Medicine, patients on the highest FDA Approves First Oral GLP-1

It binds to toxins to help eliminate them, preventing dull skin and acne caused by toxin buildup

This also helps improve spreadability and texture

Indirect Assessment of Mucosal Integrity by Potential Blood Biomarkers Both ex vivo and the direct in vivo tests for intestinal permeability are time and labor-intensive and are not readily available in most labs

Common hormonal MTHFR symptoms include: Severe PMS mood swings, breast tenderness, bloating, and irritability before periods Irregular or heavy periods unpredictable cycles or excessive menstrual bleeding Infertility and difficulty conceiving reduced egg or sperm quality or implantation issues Recurrent miscarriages often linked to elevated homocysteine and poor methylation Chronic fatigue and low energy feeling exhausted even after adequate sleep Thyroid dysfunction sluggish metabolism, weight gain, or cold sensitivity Fibrocystic breasts and ovarian cysts Endometriosis and uterine fibroids Why this happens: Poor methylation leads to oestrogen dominance (too much oestrogen relative to progesterone) because your body cant efficiently break down and eliminate used hormones

Timing your doses is also critical for success

Skin stack: GHK-Cu topical 2 % + Epithalon cycles for circadian / telomere support